数字聚合酶链反应
可用性
计算机科学
清晰
新兴技术
生化工程
人机交互
工程类
聚合酶链反应
生物
人工智能
生物化学
基因
作者
Li Ling Tan,Nitin Loganathan,Sushama Agarwalla,Chun Yang,Weiyong Yuan,Jasmine Zeng,Ruige Wu,Wei Wang,Suhanya Duraiswamy
标识
DOI:10.1080/07388551.2022.2037503
摘要
Digital polymerase chain reaction (dPCR) technology has provided a new technique for molecular diagnostics, with superior advantages, such as higher sensitivity, precision, and specificity over quantitative real-time PCRs (qPCR). Eight companies have offered commercial dPCR instruments: Fluidigm Corporation, Bio-Rad, RainDance Technologies, Life Technologies, Qiagen, JN MedSys Clarity, Optolane, and Stilla Technologies Naica. This paper discusses the working principle of each offered dPCR device and compares the associated: technical aspects, usability, costs, and current applications of each dPCR device. Lastly, up-and-coming dPCR technologies are also presented, as anticipation of how the dPCR device landscape may likely morph in the next few years.
科研通智能强力驱动
Strongly Powered by AbleSci AI